PHAXIAM Therapeutics is a therapeutics company focused on implementing a clinical strategy. It has launched a rights issue to raise approximately €10.0 million. The offering may be increased up to approximately €11.5 million if the extension clause is exercised in full. Proceeds are intended to accelerate the implementation of the company’s clinical strategy. The company invited journalists, investors, healthcare professionals, partners, and candidates to contact its teams with questions. The announcement does not provide further financial details or name participating investors.

Total raised

$11M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2024